{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:14:16Z","timestamp":1793157256676,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obesity Pillars"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.obpill.2024.100127","type":"journal-article","created":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T03:35:37Z","timestamp":1725075337000},"page":"100127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":123,"special_numbering":"C","title":["Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9389-6795","authenticated-orcid":false,"given":"Wissam","family":"Ghusn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria D.","family":"Hurtado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.obpill.2024.100127_bib1","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1056\/NEJMsa1909301","article-title":"Projected U.S. State-level prevalence of adult obesity and severe obesity","volume":"381","author":"Ward","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.obpill.2024.100127_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/164_2022_581","article-title":"Epidemiology of obesity","volume":"274","author":"S\u00f8rensen","year":"2022","journal-title":"Handb Exp Pharmacol"},{"issue":"7 Suppl","key":"10.1016\/j.obpill.2024.100127_bib3","first-page":"s176","article-title":"Obesity: definition, comorbidities, causes, and burden","volume":"22","author":"Apovian","year":"2016","journal-title":"Am J Manag Care"},{"issue":"12","key":"10.1016\/j.obpill.2024.100127_bib4","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.mayocp.2023.05.026","article-title":"Obesity: a review of pathophysiology and classification","volume":"98","author":"Busebee","year":"2023","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.obpill.2024.100127_bib5","series-title":"The health and economic costs of excess weight","article-title":"America's obesity crisis","author":"Waters","year":"2018"},{"key":"10.1016\/j.obpill.2024.100127_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101923","article-title":"Phenotype tailored lifestyle intervention on weight loss and cardiometabolic risk factors in adults with obesity: a single-centre, non-randomised, proof-of-concept study","volume":"58","author":"Cifuentes","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.obpill.2024.100127_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.obpill.2022.100046","article-title":"A\u00a0comparison between weight loss outcomes with anti-obesity medications before and during Covid-19 pandemic at a tertiary weight management center","volume":"4","author":"De la Rosa","year":"2022","journal-title":"Obesity Pillars"},{"key":"10.1016\/j.obpill.2024.100127_bib8","article-title":"Weight-centric treatment of type 2 diabetes mellitus","volume":"4","author":"Ghusn","year":"2022","journal-title":"Obes Pillars"},{"issue":"6","key":"10.1016\/j.obpill.2024.100127_bib9","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1007\/s11695-023-06622-2","article-title":"Diabetes mellitus Remission in Patients with BMI > 50 kg\/m(2) after bariatric surgeries: a real-world multi-centered study","volume":"33","author":"Ghusn","year":"2023","journal-title":"Obes Surg"},{"key":"10.1016\/j.obpill.2024.100127_bib10","first-page":"3","article-title":"Pharmacologic treatment of overweight and obesity in adults","volume":"3","author":"Tchang","year":"2015"},{"issue":"3","key":"10.1016\/j.obpill.2024.100127_bib11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1517\/13543784.17.3.263","article-title":"The future of obesity: new drugs versus lifestyle interventions","volume":"17","author":"Scheen","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"10.1016\/j.obpill.2024.100127_bib12","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/ACO.0000000000000335","article-title":"The patient with chronic heart failure undergoing surgery","volume":"29","author":"Smit-Fun","year":"2016","journal-title":"Curr Opin Anaesthesiol"},{"issue":"1","key":"10.1016\/j.obpill.2024.100127_bib13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A\u00a0randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.obpill.2024.100127_bib14","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.obpill.2024.100127_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.obpill.2024.100127_bib16","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.31982","article-title":"Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity","volume":"5","author":"Ghusn","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.obpill.2024.100127_bib17","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1159\/000518325","article-title":"Use of liraglutide 3.0 mg for weight management in a real-world setting in Switzerland","volume":"14","author":"Haase","year":"2021","journal-title":"Obes Facts"},{"issue":"5","key":"10.1016\/j.obpill.2024.100127_bib18","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41366-023-01456-5","article-title":"Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study","volume":"48","author":"Ghusn","year":"2024","journal-title":"Int J Obes"},{"issue":"6","key":"10.1016\/j.obpill.2024.100127_bib19","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1111\/dom.15523","article-title":"The association between previous use of anti-obesity medication and semaglutide weight loss outcomes. Diabetes","volume":"26","author":"Ghusn","year":"2024","journal-title":"Obes Metabol"},{"key":"10.1016\/j.obpill.2024.100127_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102625","article-title":"Weight loss outcomes with semaglutide based on diabetes severity using the individualized metabolic surgery score","volume":"72","author":"Ghusn","year":"2024","journal-title":"eClinicalMedicine"},{"issue":"1","key":"10.1016\/j.obpill.2024.100127_bib21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A\u00a0randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.obpill.2024.100127_bib22","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.obpill.2024.100127_bib23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.obpill.2024.100127_bib24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/03007995.2016.1251892","article-title":"Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects","volume":"33","author":"Bays","year":"2017","journal-title":"Curr Med Res Opin"},{"issue":"24","key":"10.1016\/j.obpill.2024.100127_bib25","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.obpill.2024.100127_bib26","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.obpill.2024.100127_bib27","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern Med"},{"issue":"6","key":"10.1016\/j.obpill.2024.100127_bib28","doi-asserted-by":"crossref","first-page":"254","DOI":"10.13105\/wjma.v3.i6.254","article-title":"Risk of pancreatic adverse events associated with the use of glucagon-like peptide-1 receptor agonist and dipeptidyl peptidase-4 inhibitor drugs: a systematic review and meta-analysis of randomized trials","volume":"3","author":"Shihab","year":"2015","journal-title":"World Journal of Meta-Analysis"},{"issue":"1","key":"10.1016\/j.obpill.2024.100127_bib29","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1038\/s41598-019-38956-2","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis","volume":"9","author":"Pinto","year":"2019","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.obpill.2024.100127_bib30","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/dom.12885","article-title":"Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes","volume":"19","author":"Storgaard","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"10.1016\/j.obpill.2024.100127_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci13111503","article-title":"GLP-1 receptor agonists and related mental health issues; insights from a range of social media platforms using a mixed-methods approach","volume":"13","author":"Arillotta","year":"2023","journal-title":"Brain Sci"},{"issue":"18","key":"10.1016\/j.obpill.2024.100127_bib32","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.21037\/atm-21-4162","article-title":"Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data","volume":"9","author":"Zhao","year":"2021","journal-title":"Ann Transl Med"},{"issue":"3","key":"10.1016\/j.obpill.2024.100127_bib33","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2174\/1573399813666170414101450","article-title":"Effect of glucagon-like peptide-1 receptor agonists on all-cause mortality and cardiovascular outcomes: a meta-analysis","volume":"14","author":"Peterson","year":"2018","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.obpill.2024.100127_bib34","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41366-023-01456-5","article-title":"Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study","volume":"48","author":"Ghusn","year":"2024","journal-title":"Int J Obes"},{"issue":"7","key":"10.1016\/j.obpill.2024.100127_bib35","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.obpill.2024.100127_bib36","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with glp-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2022","journal-title":"J\u00a0Clin Med"},{"issue":"8","key":"10.1016\/j.obpill.2024.100127_bib37","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s12630-023-02521-3","article-title":"Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report","volume":"70","author":"Gulak","year":"2023","journal-title":"Can J Anaesth"},{"issue":"8","key":"10.1016\/j.obpill.2024.100127_bib38","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1007\/s12630-023-02440-3","article-title":"Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report","volume":"70","author":"Klein","year":"2023","journal-title":"Can J Anaesth"},{"issue":"12","key":"10.1016\/j.obpill.2024.100127_bib39","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/anae.16099","article-title":"Aspiration risk with glucagon-like peptide 1 (GLP-1) agonists","volume":"78","author":"Marroquin-Harris","year":"2023","journal-title":"Anaesthesia"},{"issue":"8","key":"10.1016\/j.obpill.2024.100127_bib40","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1007\/s12630-023-02549-5","article-title":"Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide","volume":"70","author":"Sherwin","year":"2023","journal-title":"Can J Anaesth"},{"issue":"8","key":"10.1016\/j.obpill.2024.100127_bib41","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s12630-023-02550-y","article-title":"Anesthesia and glucagon-like peptide-1 receptor agonists: proceed with caution","volume":"70","author":"Jones","year":"2023","journal-title":"Canadian Journal of Anesthesia\/Journal canadien d'anesth\u00e9sie"},{"key":"10.1016\/j.obpill.2024.100127_bib42","first-page":"221","article-title":"AGA rapid clinical practice update on the management of patients taking GLP-1 receptor agonists prior to endoscopy: communication","volume":"42","author":"Hashash","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.obpill.2024.100127_bib43","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.14309\/ajg.0000000000002564","article-title":"Effect of glucagon-like PEPTIDE-1 receptor agonists on bowel preparation for colonoscopy","volume":"119","author":"Yao","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.obpill.2024.100127_bib44","first-page":"112","article-title":"As semaglutide\u2019s popularity soars, rare but serious adverse effects are emerging","volume":"32","author":"Ruder","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.obpill.2024.100127_bib45","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/14740338.2023.2295397","article-title":"The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)","volume":"23","author":"McIntyre","year":"2024","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"10.1016\/j.obpill.2024.100127_bib46","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"}],"container-title":["Obesity Pillars"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368124000299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368124000299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T23:47:43Z","timestamp":1733269663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667368124000299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":46,"alternative-id":["S2667368124000299"],"URL":"https:\/\/doi.org\/10.1016\/j.obpill.2024.100127","relation":{},"ISSN":["2667-3681"],"issn-type":[{"value":"2667-3681","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks","name":"articletitle","label":"Article Title"},{"value":"Obesity Pillars","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.obpill.2024.100127","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of Obesity Medicine Association.","name":"copyright","label":"Copyright"}],"article-number":"100127"}}